FPFranziska Preuss

Franziska Preuss

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Franziska Preuss has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Identification and Validation of 3-Cyano-Quinoline Ligands Targeting Integrin-Linked Kinase (ILK)

    by Francesco Aleksy Greco, Kamal Rayees Abdul Azeez, Marko Mitrović, Saran Aswathaman Sivashanmugam, Martin Peter Schwalm, Franziska Preuss, Deep Chatterjee, Viktoria Morasch, Sebastian Mathea, Thomas Hanke, et al.

    Integrin-linked kinase (ILK) is a pseudokinase that directly interacts with β-integrins and plays a pivotal role in regulating focal adhesion function. ILK has been implicated in the development of various diseases, particularly cancer. However, currently, no validated ligands for ILK have been reported. Here, we describe the identification of 3-cyano-quinolines that potently bind to ILK (KD = ∼250 nM), and crystallographic studies revealed a type I binding mode. A medicinal chemistry campaign exploring structure–activity relationships (SAR) using a robust parallel synthesis approach provided comprehensive SAR and identified regions amenable to modification. In addition, we demonstrated that the optimized 3-cyano-quinoline 1 (DHP) modulates actin cytoskeletal dynamics. This work highlights the first validated ILK ligands and establishes a foundation for future translational efforts, such as the development of selective PROTACs targeting ILK for degradation by the ubiquitin system.

  • Open Access

    Single particle of LRRK2 C-terminal half bound to E11 DARPin

    by Dederer V, Sanz Murillo M, Karasmanis Ep, Hatch Ks, Chatterjee D, Preuss F, Abdul Azeez Kr, Nguyen Lv, Galicia C, Dreier B, et al.

    EMPIAR, the Electron Microscopy Public Image Archive centered at EMBL-EBI, is a public resource for raw electron microscopy images related to EMDB, contains micrographs, particle sets and tilt-series.

  • Open Access

    Development of pyrazolo[1,5-a]pyrimidine based macrocyclic kinase inhibitors targeting AAK1

    by Theresa E. Mensing, Christian G. Kurz, Jennifer A. Amrhein, Theresa A. L. Ehret, Franziska Preuss, Sebastian Mathea, Marwah Karim, Do Hoang Nhu Tran, Zuzana Kadlecova, Tuomas Tolvanen, et al.

    Since the outbreak of SARS-CoV-2 in recent years, our society has become more aware that zoonotic diseases pose a real threat. Therefore, the demand for small molecules that target host proteins, essential for viral entry and replication, has increased as an interesting strategy for the development of antiviral agents, as these agents may be effective against several different pathogens. NAK kinases is one such potential target family because they are involved in a variety of cellular functions, hijacked by viruses to invade host cells, such as clathrin-mediated endocytosis. A large number of different inhibitors have already been reported targeting NAK kinases, but there are still no compounds that selectively target AAK1 over other NAK family members, in particular the closely related family member BIKE. Here, we developed a series of pyrazolo[1,5-a]pyrimidine-based macrocyclic NAK inhibitors, starting from the acyclic AAK1 inhibitor LP-935509. Through a structure-guided activity relationship study within the NAK family, we identified potent AAK1 inhibitors 16 , 18 and 27 , which show promising selectivity within the NAK family. The inhibitors showed a potent inhibition of the phosphorylation of the AP-2 complex and the antiviral activity of the compounds was evaluated against various RNA viruses.

  • Open Access

    A designed ankyrin-repeat protein that targets Parkinson’s disease-associated LRRK2

    by Verena Dederer, Marta Sanz Murillo, Eva P. Karasmanis, Kathryn S. Hatch, Deep Chatterjee, Franziska Preuss, Kamal R. Abdul Azeez, Landon Vu Nguyen, Christian Galicia, Birgit Dreier, et al.